AMT-253 ADC / Multitude Therap - LARVOL DELTA

Ongoing Phase I trial results of AMT-253, a first-in-class MUC18-targeting antibody-drug conjugate in patients with melanoma and other advanced solid tumors (ESMO 2025) - No abstract available

Clinical • Metastases • P1 data • Melanoma • Oncology • Solid Tumor • MCAM

AMT-253 in Patients With Advanced Solid Tumours (clinicaltrials.gov) - P1/2 | N=96 | Recruiting | Sponsor: Multitude Therapeutics Inc. | Trial completion date: Dec 2025 ➔ Dec 2026 | Trial primary completion date: Apr 2025 ➔ Apr 2026

Trial completion date • Trial primary completion date • Melanoma • Oncology • Solid Tumor

AMT-253 in Patients With Selected Advanced Solid Tumours (clinicaltrials.gov) - P1 | N=54 | Recruiting | Sponsor: Multitude Therapeutics (Australia) Pty Ltd | Trial completion date: Feb 2026 ➔ Dec 2026 | Trial primary completion date: Oct 2025 ➔ Sep 2026

Trial completion date • Trial primary completion date • Solid Tumor

A cell surface-binding antibody atlas nominates a MUC18-directed antibody-drug conjugate for targeting melanoma (Clin Cancer Res) - "AMT-253 exhibited MUC18-specific cytotoxicity through DNA damage and apoptosis and a strong bystander killing effect, leading to potent antitumor activities against melanoma cell line and patient-derived xenograft models. Tumor vasculature-targeting by a mouse MUC18-specific antibody-T1000-exatecan conjugate inhibited tumor growth in human melanoma xenografts."

Preclinical • Melanoma